Related Experiment Video
Updated: Jun 12, 2026
03:42
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Serum resistin: physiology, pathophysiology and implications for heart failure
Vikas Bhalla1, Andreas Kalogeropoulos, Vasiliki Georgiopoulou
1Cardiology Division, Emory University Hospital, 1365 Clifton Road NE, Suite AT 430, Atlanta, GA 30322, USA.
Biomarkers in Medicine
|June 17, 2010
Summary
Serum resistin levels are linked to heart failure risk and outcomes. This review explores resistin
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Syndrome
Background:
- Resistin, a polypeptide hormone, is implicated in insulin resistance and inflammation.
- While its role in humans is debated, serum resistin correlates with cardiovascular disease risk factors.
- Inflammation and insulin resistance are key factors in heart failure development and prognosis.
Purpose of the Study:
- To review the physiology and pathophysiology of resistin in relation to heart failure.
- To discuss the direct and indirect roles of resistin in heart failure risk and outcomes.
Main Methods:
- Literature review of studies investigating resistin and heart failure.
- Analysis of resistin's association with hyperglycemia, substrate metabolism, and inflammation (e.g., TNF-alpha).
- Examination of potential direct cardiac effects of resistin.
Main Results:
- Emerging evidence suggests a significant association between serum resistin concentrations and heart failure.
- Resistin may influence heart failure through its links to hyperglycemia, altered substrate metabolism, and inflammatory pathways.
- Potential direct effects on cardiac function warrant further investigation.
Conclusions:
- Serum resistin may serve as a biomarker for heart failure risk and prognosis.
- Understanding resistin's multifaceted role is crucial for developing targeted therapies.
- Further research is needed to elucidate the precise mechanisms underlying resistin's impact on cardiac health.
Related Concept Videos
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...